Trilostane treatment for feline hypercortisolism: Latin America multicenter study, 43 cases (2012-2022)

MICELI DD; TAVARES F, ZAPATA MONTOYA M, GARCÍA JD, PEÑA M, WEEGE K, MUSCHNER A, VECINO C, MIEROWSKI A, SCHNABEL AM, PÖPPL AG

Gotemburgo

Congreso; ECVIM-2022; 2022

Spontaneous hypercortisolism (HC), or Cushing´s syndrome, is a rare condition in cats (Felis catus). Feline HC is characterized by presence of diabetes mellitus (DM), with variable degrees of insulin resistance. Trilostane is a competitive 3-β hydroxysteroid dehydrogenase inhibitor with high safety and efficacy in canine HC. Large case series of feline HC and studies assessing the use of trilostane in cats are lacking. The aim of this study was to evaluate clinical features, clinicopathologic findings, diagnostic imaging, safety and efficacy of trilostane treatment in cats with HC. In this multicenter descriptive retrospective study, fourty-three (n=43) client-owned cats were diagnosed with spontaneous HC. All cats received an initial lower dose of trilostane (0.3-2.9 mg/kg q12h, PO) than previously reported. Values were expressed as mean±SD or, median and range (p